InspireMD, Inc. files 10-K

InspireMD, Inc. reported increased revenues in 2025 driven by the U.S. launch of its CGuard Prime stent, though the company also saw a significant increase in operating expenses, leading to a wider net loss. The company continues to focus on expanding its commercial infrastructure and product development, while acknowledging substantial doubt about its ability to continue as a going concern.